Thymoquinone / BioAv Cancer Research Results

TQ, Thymoquinone: Click to Expand ⟱
Features: Anti-oxidant, anti-tumor
Thymoquinone is a bioactive compound found in the seeds of Nigella sativa, commonly known as black seed or black cumin.
Pathways:
-Cell cycle arrest, apoptosis induction, ROS generation in cancer cells
-inhibit the activation of NF-κB, Suppress the PI3K/Akt signaling cascade
-Inhibit angiogenic factors such as VEGF, MMPs
-Inhibit HDACs, UHRF1, and DNMTs

-Note half-life 3-6hrs.
BioAv low oral bioavailability due to its lipophilic nature. Note refridgeration of Black seed oil improves the stability of TQ.
DIY: ~1 part lecithin : 2–3 parts black seed oil : 4–5 parts warm water. (chat ai)
Pathways:
- usually induce ROS production in Cancer cells, and lowers ROS in normal cells
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, GRP78↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- May Low AntiOxidant defense in Cancer Cells: NRF2↓(usually contrary), GSH↓ HO1↓(contrary), GPx↓
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, VEGF↓, FAK↓, NF-κB↓, CXCR4↓, TGF-β↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMTs↓, EZH2↓, P53↑, HSP↓, Sp proteins↓, TET↑
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, PDKs↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, α↓, ERK↓, JNK,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Target Axis Direction Label Primary Effect Notes / Cancer Relevance Ref
1 Reactive oxygen species (ROS) ↑ ROS Driver Upstream cytotoxic trigger Primary studies show TQ rapidly increases ROS; antioxidant/ROS modulation attenuates downstream effects, supporting ROS as an initiating mechanism in multiple cancer contexts (ref)
2 Glutathione (GSH) redox buffering ↓ GSH Driver Redox-collapse amplification Same prostate cancer study reports early GSH depletion alongside ROS rise; together these form a redox “one-two punch” that helps explain selective stress in tumor cells (ref)
3 Mitochondrial integrity (ΔΨm) ↓ ΔΨm Driver Mitochondrial dysfunction (MOMP axis) Primary leukemia/cancer study reports disruption of mitochondrial membrane potential after TQ exposure (mitochondrial events central to TQ-mediated death) (ref)
4 Intrinsic apoptosis (caspase-9 → caspase-3; PARP) ↑ caspases / ↑ apoptosis Driver Execution-phase cell death Same primary paper reports activation of caspases (8/9/3) with mitochondrial involvement—core evidence for apoptosis as the major outcome pathway (ref)
5 NF-κB signaling ↓ NF-κB activity Secondary Reduced pro-survival / inflammatory transcription Colon cancer work: TQ induces cell death and chemosensitizes cells by inhibiting NF-κB signaling (explicit pathway-direction support) (ref)
6 STAT3 signaling ↓ p-STAT3 / ↓ STAT3 activation Secondary Reduced survival/proliferation signaling Gastric cancer study explicitly reports TQ suppresses constitutive STAT3 activation and related signaling readouts (ref)
7 NRF2 antioxidant-response axis (NRF2/HO-1 program) ↑ NRF2 pathway (often as stress-response) Adaptive Cellular antioxidant counter-response In TNBC context, a primary study reports TQ upregulates NRF2 (and evaluates downstream immune/checkpoint consequences), consistent with NRF2 acting as an adaptive response to redox stress (ref)
8 HIF-1α hypoxia signaling ↓ HIF-1α protein / ↓ HIF-1α program Adaptive Loss of hypoxia survival signaling Renal cancer hypoxia paper identifies TQ as suppressing HIF-1α and links this to selective killing under hypoxia (ref)
9 Glycolysis / Warburg output (hypoxia-linked) ↓ glycolysis (↓ HIF-1α–mediated glycolytic genes; ↓ glycolytic metabolism) Phenotypic Metabolic suppression In hypoxic renal cancer, TQ suppresses HIF-1α–mediated glycolysis; in CRC, TQ inhibits glycolytic metabolism alongside tumor growth limitation (ref)  |  (ref)


BioAv, bioavailability: Click to Expand ⟱
Source:
Type: measurement
Bioavailability (usually in %) absorbed by the body.


Scientific Papers found: Click to Expand⟱
3422- TQ,    Thymoquinone, as a Novel Therapeutic Candidate of Cancers
- Review, Var, NA
selectivity↑, P53↑, PTEN↑, NF-kB↓, PPARγ↓, cMyc↓, Casp↑, *BioAv↓, BioAv↝, eff↑, survivin↓, Bcl-xL↓, Bcl-2↓, Akt↓, BAX↑, cl‑PARP↑, CXCR4↓, MMP9↓, VEGFR2↓, Ki-67↓, COX2↓, JAK2↓, cSrc↓, Apoptosis↑, p‑STAT3↓, cycD1/CCND1↓, Casp3↑, Casp7↑, Casp9↑, N-cadherin↓, Vim↓, Twist↓, E-cadherin↑, ChemoSen↑, eff↑, EMT↓, ROS↑, DNMT1↓, eff↑, EZH2↓, hepatoP↑, Zeb1↓, RadioS↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, *NAD↑, *SIRT1↑, SIRT1↓, *Inflam↓, *CRP↓, *TNF-α↓, *IL6↓, *IL1β↓, *eff↑, *MDA↓, *NO↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, PI3K↓, mTOR↓,
3424- TQ,    Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex
- Review, Var, NA
DNMT1↓, HDAC1↓, TumCCA↑, ROS↑, Apoptosis↑, angioG↓, TumMeta↓, selectivity↑, BioAv↓, BioAv↓, HDAC1↓, HDAC4↓, UHRF1↓, selectivity↑, G9a↓,
3571- TQ,    The Role of Thymoquinone in Inflammatory Response in Chronic Diseases
- Review, Var, NA - Review, Stroke, NA
*BioAv↓, *BioAv↑, *Inflam↓, *antiOx↑, *ROS↓, *GSH↑, *GSTs↑, *MPO↓, *NF-kB↓, *COX2↓, *IL1β↓, *TNF-α↓, *IFN-γ↓, *IL6↓, *cardioP↑, *lipid-P↓, *TAC↑, *RenoP↑, Apoptosis↑, TumCCA↑, TumCP↓, TumCMig↓, angioG↓, TNF-α↓, NF-kB↓, ROS↑, EMT↓, *Aβ↓, *p‑tau↓, *BACE↓, *TLR2↓, *TLR4↓, *MyD88↓, *IRF3↓, *eff↑, eff↑, DNAdam↑, *iNOS↓,
2084- TQ,    Thymoquinone, as an anticancer molecule: from basic research to clinical investigation
- Review, Var, NA
*ROS↓, *chemoPv↑, ROS↑, ROS⇅, MUC4↓, selectivity↑, AR↓, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, survivin↓, Mcl-1↓, VEGF↓, cl‑PARP↑, ROS↑, HSP70/HSPA5↑, P53↑, miR-34a↑, Rac1↓, TumCCA↑, NOTCH↓, NF-kB↓, IκB↓, p‑p65↓, IAP1↓, IAP2↑, XIAP↓, TNF-α↓, COX2↓, Inflam↓, α-tubulin↓, Twist↓, EMT↓, mTOR↓, PI3K↓, Akt↓, BioAv↓, ChemoSen↑, BioAv↑, PTEN↑, chemoPv↑, RadioS↑, *Half-Life↝, *BioAv↝,
2094- TQ,    Cytotoxicity of Nigella sativa Extracts Against Cancer Cells: A Review of In Vitro and In Vivo Studies
- Review, Var, NA
ROS↑, angioG↓, TumMeta↓, VEGF↓, MMPs↓, P53↑, BAX↑, Casp↑, Bcl-2↓, survivin↓, *ROS↓, ChemoSen↑, chemoP↑, MDR1↓, BioAv↓, BioAv↑,
1937- TQ,    Migration and Proliferation Effects of Thymoquinone-Loaded Nanostructured Lipid Carrier (TQ-NLC) and Thymoquinone (TQ) on In Vitro Wound Healing Models
- NA, Nor, 3T3
*ROS↓, *antiOx↓, *BioAv↓, *BioAv↑, *NO↑, *SOD↑, *GPx↑, *Catalase↑,
2106- TQ,    Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy
- Review, Var, NA
Apoptosis↑, TumCCA↑, ROS↑, *Catalase↑, *SOD↑, *GR↑, *GSTA1↓, *GPx↑, *H2O2↓, *ROS↓, *lipid-P↓, *HO-1↑, p‑Akt↓, AMPKα↑, NK cell↑, selectivity↑, Dose↝, eff↑, GSH↓, eff↓, P53↑, p‑STAT3↓, PI3K↑, MAPK↑, GSK‐3β↑, ChemoSen↑, RadioS↑, BioAv↓, NRF2↑,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

GSH↓, 1,   NRF2↑, 1,   ROS↑, 7,   ROS⇅, 1,  

Mitochondria & Bioenergetics

XIAP↓, 1,  

Core Metabolism/Glycolysis

cMyc↓, 1,   PPARγ↓, 1,   SIRT1↓, 1,  

Cell Death

Akt↓, 2,   p‑Akt↓, 1,   Apoptosis↑, 4,   BAX↑, 2,   Bcl-2↓, 3,   Bcl-xL↓, 2,   Casp↑, 2,   Casp3↑, 1,   Casp7↑, 1,   Casp9↑, 1,   IAP1↓, 1,   IAP2↑, 1,   MAPK↑, 1,   Mcl-1↓, 1,   survivin↓, 3,  

Kinase & Signal Transduction

AMPKα↑, 1,   cSrc↓, 1,  

Transcription & Epigenetics

EZH2↓, 1,  

Protein Folding & ER Stress

HSP70/HSPA5↑, 1,  

DNA Damage & Repair

DNAdam↑, 1,   DNMT1↓, 2,   G9a↓, 1,   P53↑, 4,   cl‑PARP↑, 2,   UHRF1↓, 1,  

Cell Cycle & Senescence

cycD1/CCND1↓, 2,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State

EMT↓, 3,   GSK‐3β↑, 1,   HDAC↓, 1,   HDAC1↓, 3,   HDAC2↓, 1,   HDAC3↓, 1,   HDAC4↓, 1,   miR-34a↑, 1,   mTOR↓, 2,   NOTCH↓, 1,   PI3K↓, 2,   PI3K↑, 1,   PTEN↑, 2,   p‑STAT3↓, 2,  

Migration

E-cadherin↑, 1,   Ki-67↓, 1,   MMP9↓, 1,   MMPs↓, 1,   MUC4↓, 1,   N-cadherin↓, 1,   Rac1↓, 1,   TumCMig↓, 1,   TumCP↓, 1,   TumMeta↓, 2,   Twist↓, 2,   Vim↓, 1,   Zeb1↓, 1,   α-tubulin↓, 1,  

Angiogenesis & Vasculature

angioG↓, 3,   VEGF↓, 2,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling

COX2↓, 2,   CXCR4↓, 1,   Inflam↓, 1,   IκB↓, 1,   JAK2↓, 1,   NF-kB↓, 3,   NK cell↑, 1,   p‑p65↓, 1,   TNF-α↓, 2,  

Hormonal & Nuclear Receptors

AR↓, 1,  

Drug Metabolism & Resistance

BioAv↓, 5,   BioAv↑, 2,   BioAv↝, 1,   ChemoSen↑, 4,   Dose↝, 1,   eff↓, 1,   eff↑, 5,   MDR1↓, 1,   RadioS↑, 3,   selectivity↑, 5,  

Clinical Biomarkers

AR↓, 1,   EZH2↓, 1,   Ki-67↓, 1,  

Functional Outcomes

chemoP↑, 1,   chemoPv↑, 1,   hepatoP↑, 1,  
Total Targets: 92

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↓, 1,   antiOx↑, 1,   Catalase↑, 3,   GPx↑, 3,   GSH↑, 2,   GSTA1↓, 1,   GSTs↑, 1,   H2O2↓, 1,   HO-1↑, 1,   lipid-P↓, 2,   MDA↓, 1,   MPO↓, 1,   ROS↓, 5,   SOD↑, 3,   TAC↑, 1,  

Core Metabolism/Glycolysis

NAD↑, 1,   SIRT1↑, 1,  

Cell Death

iNOS↓, 1,  

Angiogenesis & Vasculature

NO↓, 1,   NO↑, 1,  

Immune & Inflammatory Signaling

COX2↓, 1,   CRP↓, 1,   IFN-γ↓, 1,   IL1β↓, 2,   IL6↓, 2,   Inflam↓, 2,   MyD88↓, 1,   NF-kB↓, 1,   TLR2↓, 1,   TLR4↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission

p‑tau↓, 1,  

Protein Aggregation

Aβ↓, 1,   BACE↓, 1,  

Hormonal & Nuclear Receptors

GR↑, 1,  

Drug Metabolism & Resistance

BioAv↓, 3,   BioAv↑, 2,   BioAv↝, 1,   eff↑, 2,   Half-Life↝, 1,  

Clinical Biomarkers

CRP↓, 1,   IL6↓, 2,  

Functional Outcomes

cardioP↑, 1,   chemoPv↑, 1,   RenoP↑, 1,  

Infection & Microbiome

IRF3↓, 1,  
Total Targets: 46

Scientific Paper Hit Count for: BioAv, bioavailability
7 Thymoquinone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:162  Target#:792  State#:%  Dir#:1
wNotes=0 sortOrder:rid,rpid

 

Home Page